Advertisement
A vs SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- A (Agilent Technologies) has outperformed SYK (Stryker) year-to-date with a 14.68% gain versus 6.14%, reflecting stronger momentum in life sciences demand.
- SYK boasts a larger market cap of $126 billion compared to A's $32.65 billion, underscoring its dominant position in medical devices.
- Recent market activity shows both stocks pulling back from 52-week highs, with A trading near the lower end of its range amid post-earnings digestion.
- SYK exhibits lower volatility (beta of 0.93) than A (1.30), appealing to risk-averse investors.
- Analyst price targets suggest upside potential: $160.69 average for A (39% from current levels) and $419.11 for SYK (27% upside).
- Growth metrics favor SYK with 11.4% revenue growth and 55.5% EPS growth, outpacing A's figures.
Introduction
Agilent Technologies (A) and Stryker Corporation (SYK) represent key players in the healthcare and life sciences sectors, where innovation drives demand for advanced instruments and medical devices. This comparison analyzes their business models, recent performance, and market positioning to aid traders seeking short-term opportunities and investors focused on long-term growth. With both stocks experiencing volatility in recent market activity, understanding relative strengths in diagnostics, orthopedics, and lab solutions can inform portfolio decisions amid evolving healthcare trends.
A Overview and Recent Performance
Agilent Technologies (A) is a global leader in life sciences, diagnostics, and applied chemical markets, offering chromatography systems, mass spectrometry, genomics tools, and laboratory services through segments like Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets. In recent weeks, the stock has traded around $115.62, down from its 52-week high of $160.27 but above the low of $104.10, reflecting a year-to-date gain of 14.68%. Post its Q1 fiscal 2026 earnings in late February—where revenue reached $1.80 billion amid a China slowdown—shares softened due to mixed results, with EPS at $1.36 and guidance maintained for 4-6% core growth. Sentiment has been influenced by collaborations in precision oncology and litigation resolutions, though broader market caution on growth stocks has pressured performance. Key metrics include a P/E ratio (price-to-earnings) of 25.51, ROE (return on equity) of 19.95%, and beta of 1.30 indicating higher volatility.
SYK Overview and Recent Performance
Stryker Corporation (SYK) specializes in medical technology, focusing on MedSurg and Neurotechnology (surgical equipment, endoscopy, AI-assisted care) and Orthopaedics (joint implants, robotics like Mako). Shares recently closed at $329.01, near the 52-week low of $319.32 after a high of $404.87, with a year-to-date return of 6.14%. Anticipation builds for Q1 2026 earnings on April 30, expecting EPS of $2.98 and revenue of $6.29 billion, supported by 10.2% organic growth trends. Recent cyberattack challenges and share price momentum concerns have tempered gains, yet strong historical EPS growth (55.5%) and analyst optimism persist. Financials show a P/E of 39.17, ROE of 15.08%, debt-to-equity of 72.97%, and a lower beta of 0.93 for relative stability.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection from hundreds of AI Trading Bots that analyze and trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots employ varying approaches—from swing trading to pattern recognition—delivering performance stats like win rates often exceeding 60%, average annualized returns in the double digits, and thousands of executed trades. Only the highest-performing and most adaptive bots earn a spot in this trending section, tailored to current volatility and sector rotations. Traders can explore real-time signals, backtested results, and customizable portfolios. Visit the Trending AI Robots page to discover bots potentially suited for stocks like A and SYK.
Head-to-Head Comparison
While both operate in healthcare, A emphasizes lab instrumentation and diagnostics for research, contrasting SYK’s direct medical device focus on surgeries and implants. Growth drivers differ: A benefits from biopharma demand but faces China exposure risks, whereas SYK leverages elective procedures and robotics amid aging populations. Recent momentum favors A YTD, but SYK shows superior revenue (11.4%) and EPS growth. Risk factors include A’s higher beta and post-earnings dips versus SYK’s cyber issues. Sector-wise, both gain from medtech tailwinds, but SYK’s scale offers better resilience; sentiment tilts toward SYK pre-earnings.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward SYK with moderate confidence, citing its trend consistency, lower beta for stability, robust organic growth trajectory, and positive pre-earnings positioning relative to A’s recent volatility and regional headwinds. Factors like superior EPS expansion and market cap dominance enhance its appeal in the near term, though A could rebound on life sciences catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and SYK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- SYK’s TA Score: 4 bullish, 3 bearish.
Price Growth
A (@Medical Specialties) experienced а -1.92% price change this week, while SYK (@Medical/Nursing Services) price change was +0.71% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.17%. For the same industry, the average monthly price growth was +8.92%, and the average quarterly price growth was -2.29%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +23.45%. For the same industry, the average monthly price growth was +12.35%, and the average quarterly price growth was -13.81%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (-1.17% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+23.45% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | SYK | A / SYK | |
| Capitalization | 35.9B | 118B | 30% |
| EBITDA | 1.96B | 6.44B | 30% |
| Gain YTD | -6.241 | -12.188 | 51% |
| P/E Ratio | 25.51 | 35.63 | 72% |
| Revenue | 7.23B | 25.3B | 29% |
| Total Cash | 1.81B | 2.97B | 61% |
| Total Debt | 3.36B | 14.7B | 23% |
A | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 92 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 67 | |
SMR RATING 1..100 | 44 | 57 | |
PRICE GROWTH RATING 1..100 | 47 | 62 | |
P/E GROWTH RATING 1..100 | 62 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 41 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is in the same range as SYK (9) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (67) in the Medical Specialties industry is somewhat better than the same rating for A (100) in the Biotechnology industry. This means that SYK’s stock grew somewhat faster than A’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as SYK (57) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's Price Growth Rating (47) in the Biotechnology industry is in the same range as SYK (62) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's P/E Growth Rating (62) in the Biotechnology industry is in the same range as SYK (80) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
| A | SYK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 71% | N/A |
| Stochastic ODDS (%) | 3 days ago 57% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 59% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 58% | 3 days ago 52% |
| Advances ODDS (%) | 6 days ago 60% | 16 days ago 55% |
| Declines ODDS (%) | 4 days ago 62% | 10 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 50% | 3 days ago 81% |
| Aroon ODDS (%) | 3 days ago 67% | 3 days ago 44% |
Advertisement
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.